No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis

被引:0
|
作者
Blok, P
Craanen, ME
Dekker, W
Offerhaus, GJA
Tytgat, GNJ
机构
[1] Westeinde Ziekenhuis, Dept Pathol, NL-2501 CK The Hague, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Gastroenterol, NL-1066 CX Amsterdam, Netherlands
[4] Kennemer Gasthuis, Dept Internal Med, NL-2035 RC Haarlem, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
来源
JOURNAL OF PATHOLOGY | 1998年 / 186卷 / 01期
关键词
early gastric cancer; p; 53; MDM2; carcinogenesis; immunohistochemistry;
D O I
10.1002/(SICI)1096-9896(199809)186:1<36::AID-PATH150>3.0.CO;2-R
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inactivation of wild-type p53 during gastric carcinogenesis is usually caused by mutations within exons 5-8 of the p53 gene leading to mutated, usually immunohistochemically detectable p53 proteins, However, functional inactivation of wild-type p53, mimicking mutational inactivation, may also result from binding to overexpressed MDM2 protein, While these two mechanisms of p53 inactivation are considered to be mutually exclusive, no data exist as to whether MDM2 overexpression occurs during gastric carcinogenesis. MDM2 protein overexpression was therefore studied in relation to p53 protein accumulation in gastric carcinogenesis. Forty-five paraffin-embedded gastrectomy specimens from early gastric carcinomas were examined for the presence of chronic active gastritis, chronic atrophic gastritis, subtypes of intestinal metaplasia, and dysplasia, The Lauren type was reassessed for all early carcinomas. p53 protein accumulation was examined using the monoclonal antibody DO-7. MDM2 protein overexpression was assessed with the monoclonal antibody SMP-14. Complete absence of nuclear p53 protein accumulation was observed in chronic active gastritis, chronic atrophic gastritis, and intestinal metaplasia, irrespective of the subtype, In gastric dysplasia (one mild, two moderate, one severe), only severe dysplasia was p53-positive, Intestinal-type (n=20) and diffuse-type early gastric carcinoma (n=25) were p53-positive in 70 and 52 per cent of the cases, respectively. MDM2 protein overexpression was not observed during gastric carcinogenesis, either in the p53-positive or in the p53-negative cases, In conclusion, it appears that functional inactivation of wild-type p53 by MDM2 protein overexpression plays no role in (early) gastric carcinogenesis. (C) 1998 John Wiley & Sons, Ltd.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 50 条
  • [41] Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification
    Knights, CD
    Liu, YG
    Appella, E
    Kulesz-Martin, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (52) : 52890 - 52900
  • [42] MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: Association with wild-type p53 accumulation
    Pruneri, G
    Pignataro, L
    Carboni, N
    Luminari, S
    Capaccio, P
    Neri, A
    Buffa, R
    MODERN PATHOLOGY, 1997, 10 (08) : 785 - 792
  • [43] P53 Mdm2 Inhibitors
    Khoury, Kareem
    Doemling, Alex
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
  • [44] Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features
    Horie, S
    Maeta, H
    Endo, K
    Ueta, T
    Takashima, K
    Terada, T
    PATHOLOGY INTERNATIONAL, 2001, 51 (01) : 11 - 15
  • [45] p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
    Lindström, MS
    Klangby, U
    Wiman, KG
    ONCOGENE, 2001, 20 (17) : 2171 - 2177
  • [46] p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
    Mikael S Lindström
    Ulf Klangby
    Klas G Wiman
    Oncogene, 2001, 20 : 2171 - 2177
  • [47] MDM2与p53
    金晶
    刘耕陶
    癌症, 2001, (06) : 663 - 666
  • [48] Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function
    D Chen
    Z Zhang
    M Li
    W Wang
    Y Li
    E R Rayburn
    D L Hill
    H Wang
    R Zhang
    Oncogene, 2007, 26 : 5029 - 5037
  • [49] MDM2 and BCL-2: to p53 or not to p53?
    Wang, Eunice S.
    BLOOD, 2023, 141 (11) : 1237 - 1238
  • [50] BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53
    Luo, Yanwei
    Wang, Xinye
    Niu, Weihong
    Zhou, Yao
    Li, Mengna
    Ma, Jinqi
    Yang, Jing
    Fan, Songqing
    Zeng, Zhaoyang
    Xiong, Wei
    Li, Xiaoling
    Li, Guiyuan
    Xiao, Jidong
    Zhou, Ming
    JOURNAL OF CANCER, 2022, 13 (05): : 1436 - 1448